24 Hour IOP Lowering Efficacy of AL-3789

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study was to describe the intraocular pressure-lowering efficacy of AL-3789 over a 24-hour period in patients with open-angle glaucoma compared to an untreated control. Patients received one treatment of AL-3789. Twenty-eight days after treatment, IOP was measured every 4 hours, beginning at 8 AM for 24 hours.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research

Criteria

Inclusion Criteria:

• Diagnosis of open-angle glaucoma and treated for at least 30 days prior to Screening Visit with a topical prostaglandin analog as monotherapy.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Pregnant, intend to become pregnant, breastfeeding.

• Difference in IOP greater than 3 mm Hg between eyes at Screening Visit.

• Any form of glaucoma other than open-angle glaucoma.

• Other protocol-defined exclusion criteria may apply.